表柔比星联合紫杉醇脂质体新辅助化疗治疗三阴性乳腺癌的效果观察  

Efficacy of Epirubicin Combined with Paclitaxel Liposome Neoadjuvant Chemotherapy in the Treatment of Triple Negative Breast Cancer

作　　者：张杨 ZHANG Yang(Department of Radiotherapy,Dandong First Hospital,Dandong 118000,China)

机构地区：[1]丹东市第一医院放疗科,辽宁丹东118000

出　　处：《中国医药指南》2020年第33期48-49,共2页Guide of China Medicine

摘　　要：目的探讨表柔比星联合紫杉醇脂质体新辅助化疗治疗三阴性乳腺癌的效果。方法选择2011年4月至2014年7月70例三阴性乳腺癌患者,随机分为两组各35例,研究组采取表柔比星联合紫杉醇脂质体新辅助化疗,对照组仅采取表柔比星新辅助化疗。比较两组的近远期疗效、不良反应及远期生存预后情况。结果研究组有效率、获益率、3年无病生存率、总生存率、5年无病生存率均高于对照组,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论三阴性乳腺癌采取表柔比星联合紫杉醇脂质体新辅助化疗治疗,可显著提升临床疗效,延长患者的生存期。Objective To investigate the efficacy of epirubicin combined with paclitaxel liposome neoadjuvant chemotherapy in the treatment of triple negative breast cancer.Methods Seventy cases of triple negative breast cancer patients from April 2011 to July 2014 were randomly divided into two groups,35 cases in each group.Epirubicin combined with paclitaxel liposome neoadjuvant chemotherapy was used in the study group,and only epirubicin neoadjuvant chemotherapy was used in the control group.The short-term and long-term efficacy,adverse reactions and long-term survival prognosis of the two groups were compared.Results The effective rate,benefit rate,3-year disease-free survival rate,overall survival rate and 5-year disease-free survival rate of the study group were all higher than those of the control group,the difference were statistically significant(P<0.05).There were no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Triple negative breast cancer treated with epirubicin combined with paclitaxel liposome neoadjuvant chemotherapy can significantly improve the clinical efficacy and prolong the survival period of patients.

关 键 词：三阴性乳腺癌 表柔比星 紫杉醇脂质体 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]